Brief: Camp4 Therapeutics - Under Deal With GSK, Eligible For Up To $440 Million In Milestone Payments
18/12/2025 12:10
Dec 18 (Reuters) - CAMP4 Therapeutics Corp CAMP.O: CAMP4 THERAPEUTICS - UNDER DEAL WITH GSK, ELIGIBLE FOR UP TO $440 MILLION IN MILESTONE PAYMENTS - SEC FILING Further company coverage: CAMP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CAMP4 Therapeutics
See all newsBrief: Camp4 Therapeutics Receives Authorization In The United Kingdom For Phase 1/2 Human Clinical Trial Of Cmp-002 In Patients With Syngap1-Related Disorder
Camp4 Therapeutics Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Camp4 Therapeutics Q2 Loss Per Share Misses Estimates On Non: cash derivative charge
Camp4 Therapeutics Corp Expected To Post A Loss Of 21 Cents A Share: Earnings Preview
U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation